TTRX
HEALTHCARETurn Therapeutics Inc
$3.79+0.10 (+2.57%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving TTRX Today?
No stock-specific AI insight has been generated for TTRX yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$2.57$10.00
$3.80
Fundamentals
Market Cap$113M
P/E Ratio—
EPS$-0.12
Dividend Yield—
Dividend / Share—
ROE-1.4%
Profit Margin—
Debt / Equity—
Trading
Volume13K
Avg Volume (10D)—
Shares Outstanding29.8M
TTRX News
20 articles- Turn Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate UpdatesYahoo Finance·Mar 31, 2026
- Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital GroupYahoo Finance·Mar 24, 2026
- Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical StrategyMarketbeat·Mar 2, 2026
- Turn Therapeutics Appoints Dr. Robert Redfield as Senior Advisor of Health Policy and Regulatory AffairsYahoo Finance·Feb 17, 2026
- Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare ConferencesYahoo Finance·Feb 9, 2026
- Positive Signs As Multiple Insiders Buy Turn Therapeutics StockYahoo Finance·Feb 4, 2026
- Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 12, 2026
- Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they haven’t stopped buyingYahoo Finance·Jan 8, 2026
- Turn Therapeutics Appoints Martin Dewhurst to its Board of DirectorsYahoo Finance·Jan 7, 2026
- Here Are Monday’s Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More247 Wall St·Dec 29, 2025
- Turn Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesYahoo Finance·Nov 13, 2025
- Turn Therapeutics CEO, Bradley Burnam, Speaks with Former Director of the Centers for Disease Control and Prevention Dr. Robert Redfield, M.D.Yahoo Finance·Nov 11, 2025
- Turn Therapeutics’ GX-03 Technology Named as One of “Five Novel Mechanisms Reshaping Atopic Dermatitis Treatment” by Patient Care Online MagazineYahoo Finance·Nov 11, 2025
- Turn Therapeutics Appoints Veteran Capital Markets Executive Andrew Scott as Vice President of Corporate CommunicationsYahoo Finance·Nov 4, 2025
- Turn Therapeutics Enters Global Supply, Development, and License Agreement with Leading Medical-Surgical Product Manufacturer and Distributor MedlineYahoo Finance·Oct 30, 2025
- Turn Therapeutics Provides Shareholder Update Highlighting Continued Execution Across Clinical and Strategic MilestonesYahoo Finance·Oct 22, 2025
- Turn Therapeutics Launches Webinar Series for Ongoing Shareholder Engagement, First Session October 22, 2025Yahoo Finance·Oct 20, 2025
- Turn Therapeutics Appoints Dr. Kent Kester to Board of DirectorsYahoo Finance·Oct 15, 2025
- Turn Therapeutics Appoints Arthur Golden to Board of DirectorsYahoo Finance·Oct 14, 2025
- Turn Therapeutics to Commence Trading Today on NasdaqYahoo Finance·Oct 8, 2025
All 20 articles loaded
Price Data
Open$3.68
Previous Close$3.70
Day High$3.84
Day Low$3.68
52 Week High$10.00
52 Week Low$2.57
52-Week Range
$2.57$10.00
$3.80
Fundamentals
Market Cap$113M
P/E Ratio—
EPS$-0.12
Dividend Yield—
Dividend / Share—
ROE-1.4%
Profit Margin—
Debt / Equity—
Trading
Volume13K
Avg Volume (10D)—
Shares Outstanding29.8M
About Turn Therapeutics Inc
Turn Therapeutics Inc., is a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company is headquartered in Westlake Village, California.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—